Consolidated Statement Of Cash Flows

Solasia Pharma K.K. - Filing #7272454

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss)
JPY
-1,941,000,000 JPY
JPY
JPY
JPY
JPY
-1,941,000,000 JPY
JPY
JPY
-1,112,000,000 JPY
JPY
JPY
JPY
JPY
JPY
-1,112,000,000 JPY
Impairment losses (reversal of impairment losses)
959,000,000 JPY
JPY
Finance income
-3,000,000 JPY
-10,000,000 JPY
Finance costs
1,000,000 JPY
0 JPY
Share of loss (profit) of investments accounted for using equity method
4,000,000 JPY
5,000,000 JPY
Decrease (increase) in inventories
-5,000,000 JPY
-108,000,000 JPY
Other
37,000,000 JPY
-7,000,000 JPY
Subtotal
-1,030,000,000 JPY
-332,000,000 JPY
Interest received
0 JPY
0 JPY
Interest paid
-1,000,000 JPY
0 JPY
Net cash provided by (used in) operating activities
-1,033,000,000 JPY
-359,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-1,000,000 JPY
0 JPY
Other
0 JPY
JPY
Net cash provided by (used in) investing activities
0 JPY
0 JPY
Cash flows from financing activities
Proceeds from issuance of bonds
500,000,000 JPY
JPY
Redemption of bonds
-500,000,000 JPY
JPY
Proceeds from issuance of shares
1,215,000,000 JPY
318,000,000 JPY
Net cash provided by (used in) financing activities
1,180,000,000 JPY
275,000,000 JPY
Net increase (decrease) in cash and cash equivalents
146,000,000 JPY
-83,000,000 JPY
Cash and cash equivalents
886,000,000 JPY
728,000,000 JPY
803,000,000 JPY
Effect of exchange rate changes on cash and cash equivalents
11,000,000 JPY
7,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.